Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease
15 November 2022
Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.
Three NIHR HTA grants awarded to Professor Tim Theologis
4 October 2022
Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.
Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury
23 August 2022
New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.
Oxford receives NIHR funding to test anti-TNF on post operative delirium
27 July 2022
Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.
Emergency departments to use the FORCE pathway for wrist fractures in children
6 July 2022
New research from the University of Oxford has shown that doctors can simplify treatment for the most common fracture in children, reducing NHS costs.
Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination
29 June 2022
The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.
Celebrating Clinical Trials Day at NDORMS
20 May 2022
To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.
Breakthrough in treatment for Dupuytren’s disease
29 April 2022
Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.
Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain
6 April 2022
A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.
Cemented hip replacement improves quality of life for patients over 60
10 February 2022
The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.
FUTURE-GB looking ahead to 2022
2 February 2022
FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.
Plaster cast or metal pins to treat a broken wrist? The results are in.
19 January 2022
An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.
SCIENCE spreads across the world
14 July 2021
Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.